---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-066656"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:26:41.712365+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical receives FDA approval for RECELL GO next-gen skin harvesting device

## Summary
- FDA approved RECELL GO next-gen autologous cell harvesting device for thermal burn wounds and full-thickness skin defects.
- Device reduces training burden, improves OR workflow, and controls enzyme incubation for optimal cell yield; launch June 2024.
- Clinical benefits: uses less donor skin, reduces pain, speeds closure, cuts procedures, shortens hospital stays for burns <50% TBSA.

## SEC filing metadata
- accession: 0000950170-24-066656
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000095017024066656/0000950170-24-066656-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000095017024066656/rcel-20240529.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-066656
- JSON: https://secwatch.observer/filing/0000950170-24-066656.json
- Plain text: https://secwatch.observer/filing/0000950170-24-066656.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.